GT200400242A - Uso extendido de combinacion que comprende estrogenos y progestina. - Google Patents

Uso extendido de combinacion que comprende estrogenos y progestina.

Info

Publication number
GT200400242A
GT200400242A GT200400242A GT200400242A GT200400242A GT 200400242 A GT200400242 A GT 200400242A GT 200400242 A GT200400242 A GT 200400242A GT 200400242 A GT200400242 A GT 200400242A GT 200400242 A GT200400242 A GT 200400242A
Authority
GT
Guatemala
Prior art keywords
progestine
strogens
combination
composition
extended use
Prior art date
Application number
GT200400242A
Other languages
English (en)
Inventor
Bernd Dusterberg
Jan Endrikat
Rolf Schurmann
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34443011&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GT200400242(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of GT200400242A publication Critical patent/GT200400242A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

UNA PREPARACION FARMACEUTICA PARA OBTENER UN TRATAMIENTO HORMONAL CONTINUO DURANTE UN PERIODO DE TIEMPO DESEADO MAS PROLONGADO QUE 2128 DIAS, QUE COMPRENDE UNA PRIMERA COMPOSICION QUE CONTIENE AL MENOS UN ESTROGENO Y/O AL MENOS UNA PROGESTINA EN UNA CANTIDAD PREDETERMINADA, QUE SE ADMINISTRA EN LOS PRIMEROS 2128 DIAS, Y UNA SEGUNDA COMPOSICION QUE CONTIENE AL MENSO UN ESTROGENO Y/O AL MENOS UNA PROGESTINA, EN UNA CANTIDAD PREDETERMINADA MAYOR QUE LA CANTIDAD DE LA PRIMERA COMPOSICION, Y QUE COMPRENDE UNA SECUENCIA MONO O MULTIFASICA DE DOSIFICACIONES FARMACEUTICAS.
GT200400242A 2003-11-26 2004-11-25 Uso extendido de combinacion que comprende estrogenos y progestina. GT200400242A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03090405A EP1535618A1 (en) 2003-11-26 2003-11-26 Pharmaceutical preparation for continuous hormonal treatment over a period of longer than 21-28 days comprising two estrogen and/or progestin compositions

Publications (1)

Publication Number Publication Date
GT200400242A true GT200400242A (es) 2006-01-18

Family

ID=34443011

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200400242A GT200400242A (es) 2003-11-26 2004-11-25 Uso extendido de combinacion que comprende estrogenos y progestina.

Country Status (22)

Country Link
US (1) US20080234240A1 (es)
EP (3) EP1535618A1 (es)
JP (1) JP2007512291A (es)
KR (1) KR20060126671A (es)
CN (1) CN1905885A (es)
AR (1) AR046671A1 (es)
AU (1) AU2004292778A1 (es)
BR (1) BRPI0416924A (es)
CA (1) CA2547051A1 (es)
CR (1) CR8450A (es)
EA (1) EA200600964A1 (es)
EC (1) ECSP066674A (es)
GT (1) GT200400242A (es)
IL (1) IL175858A0 (es)
NO (1) NO20062945L (es)
PA (1) PA8618301A1 (es)
PE (1) PE20051038A1 (es)
RS (1) RS20060348A (es)
TW (1) TW200529862A (es)
UY (1) UY28631A1 (es)
WO (1) WO2005051400A1 (es)
ZA (1) ZA200605224B (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070111975A1 (en) * 2004-10-07 2007-05-17 Duramed Pharmaceuticals, Inc. Methods of Hormonal Treatment Utilizing Ascending-Dose Extended Cycle Regimens
DE102004062182B4 (de) * 2004-12-20 2007-06-06 Bayer Schering Pharma Ag Transdermales Pflaster mit Progesteron A-Spezifische Liganden (PRASL) als Wirkstoff
US20090181075A1 (en) * 2005-07-15 2009-07-16 Gordon Ryan D Drospirenone containing transdermal drug delivery devices and methods of delivery thereof
EP1774970A1 (de) * 2005-10-13 2007-04-18 Bayer Schering Pharma AG Verfahren zur Herstellung eines einphasigen pharmazeutischen Präparates zur Therapie der dysfunktionellen uterinen Blutung, enthaltend Ethinylestradiol und Dienogest
DE102005056527A1 (de) * 2005-11-25 2007-07-12 Grünenthal GmbH Verwendung einer Kombination aus Ethinylestradiol und Chlormadinonacetat zur Herstellung eines Arzneimittels
WO2008018872A1 (en) * 2006-08-10 2008-02-14 Drugtech Corporation Therapeutic methods of using estrogen compositions
EP1977752A1 (de) * 2007-03-01 2008-10-08 Bayer Schering Pharma Aktiengesellschaft Pharmazeutische Zubereitung zur Verminderung der Endometriose
DE102007011105A1 (de) * 2007-03-02 2008-09-04 Bayer Schering Pharma Aktiengesellschaft Mineralcorticoid-Rezeptor-Antagonisten zur Behandlung von Endometriose
EP2383279A1 (en) 2011-07-19 2011-11-02 Pantarhei Bioscience B.V. Process for the preparation of estetrol
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
PT2782584T (pt) 2011-11-23 2021-09-02 Therapeuticsmd Inc Preparações e terapias de substituição para hormonoterapias naturais combinadas
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
CA2947767A1 (en) 2014-05-22 2015-11-26 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
CN104546870B (zh) * 2015-01-27 2018-01-12 唐凡兰 一种避孕药
LT3106148T (lt) 2015-06-18 2018-06-25 Mithra Pharmaceuticals S.A. Burnoje disperguojamos dozės vienetas, turintis estetrolio komponentą
TN2017000497A1 (en) 2015-06-18 2019-04-12 Mithra Pharmaceuticals S A Orodispersible dosage unit containing an estetrol component
CN107750157B (zh) 2015-06-18 2021-07-13 埃斯特拉私人有限责任公司 含雌四醇的口腔分散片剂
ES2877186T3 (es) 2015-06-18 2021-11-16 Estetra Sprl Comprimido orodispersable que contiene estetrol
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
KR20180126582A (ko) 2016-04-01 2018-11-27 쎄러퓨틱스엠디, 인코퍼레이티드 스테로이드 호르몬 약제학적 조성물
KR20220144885A (ko) 2016-08-05 2022-10-27 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 월경통 및 생리통의 관리방법
JP2018083806A (ja) * 2016-11-11 2018-05-31 持田製薬株式会社 月経困難症治療用組成物
UA126746C2 (uk) * 2018-02-07 2023-01-18 Естетра Спрл Композиція контрацептива зі зниженими ефектами щодо серцево-судинної системи
JOP20200260A1 (ar) 2018-04-19 2019-10-19 Estetra Sprl مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
CL2021001762A1 (es) * 2021-07-01 2022-01-21 Univ Pontificia Catolica Chile Uso del estetrol como tratamiento para la endometriosis

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3969502A (en) * 1972-04-14 1976-07-13 Schering Aktiengesellschaft Method for contraception by the administration of sequential contraceptive preparations
AU581486B2 (en) * 1985-12-30 1989-02-23 Warner-Lambert Company Graduated estrogen contraceptive
US5010070A (en) * 1987-06-15 1991-04-23 Warner-Lambert Company Graduated estrogen contraceptive
DK174724B1 (da) 1986-07-15 2003-10-06 Wyeth Corp Anvendelse af et præparat omfattende et østrogen og et progestogen til fremstilling af en dosisform til tilvejebringelse af hormonerstatningsterapi og kontraception til kvinder i præmenopausen samt pakning til tilvejebringelse af præparatet
US5276022A (en) * 1987-09-24 1994-01-04 Jencap Research Ltd. Hormone preparation and method
NZ226316A (en) * 1987-09-24 1991-10-25 Jencap Research Ltd Pharmaceutical contraceptive preparations and packages containing from 20-35 unit dosages comprising an estrogen and a progestin; the unit dosages having alternating estrogen and progestin dominance
IE71203B1 (en) * 1990-12-13 1997-02-12 Akzo Nv Low estrogen oral contraceptives
DE4411585A1 (de) * 1994-03-30 1995-10-05 Schering Ag Pharmazeutisches Kombinationspräparat zur hormonalen Kontrazeption
DE19540253C2 (de) * 1995-10-28 1998-06-04 Jenapharm Gmbh Mehrphasenpräparat zur Kontrazeption auf der Basis natürlicher Estrogene
DE19549264A1 (de) * 1995-12-23 1997-06-26 Schering Ag Verfahren und Kit zur Kontrazeption
EP0921804B1 (en) * 1996-07-26 2003-09-10 Wyeth Biphasic oral contraceptive method and kit comprising a combination of a progestin and estrogen
US6028064A (en) * 1996-09-13 2000-02-22 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of progestin products
DE19654609A1 (de) * 1996-12-20 1998-06-25 Schering Ag Therapeutische Gestagene zur Behandlung von Premenstrual Dysphoric Disorder
US5898032A (en) * 1997-06-23 1999-04-27 Medical College Of Hampton Roads Ultra low dose oral contraceptives with less menstrual bleeding and sustained efficacy
ATE279198T1 (de) 1997-08-27 2004-10-15 Ortho Mcneil Pharm Inc Kombinationen von endometrium schonenden gestagenen und endometrium atrophisierenden gestagenen mit estrogenen, bei der oralen empfängnisverhütung
US20020193356A1 (en) * 2001-05-23 2002-12-19 Van Beek Agatha Antonia Magdalena Means and method for hormonal contraception
JP2004521951A (ja) * 2001-07-13 2004-07-22 シエーリング アクチエンゲゼルシャフト Ｈｒｔのためのドロスピレノン及びエストロゲンスルファメートの組み合わせ
US7320969B2 (en) 2001-12-05 2008-01-22 Duramed Pharmaceuticals, Inc. Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology

Also Published As

Publication number Publication date
EP1689409A1 (en) 2006-08-16
IL175858A0 (en) 2006-10-05
WO2005051400A1 (en) 2005-06-09
JP2007512291A (ja) 2007-05-17
PE20051038A1 (es) 2006-02-08
ZA200605224B (en) 2009-10-28
CN1905885A (zh) 2007-01-31
UY28631A1 (es) 2005-06-30
EP1535618A1 (en) 2005-06-01
NO20062945L (no) 2006-08-23
AU2004292778A1 (en) 2005-06-09
ECSP066674A (es) 2006-10-25
RS20060348A (en) 2008-08-07
BRPI0416924A (pt) 2007-01-16
EA200600964A1 (ru) 2006-10-27
TW200529862A (en) 2005-09-16
CR8450A (es) 2007-06-06
PA8618301A1 (es) 2006-05-16
AR046671A1 (es) 2005-12-14
CA2547051A1 (en) 2005-06-09
US20080234240A1 (en) 2008-09-25
KR20060126671A (ko) 2006-12-08
EP2044942A1 (en) 2009-04-08

Similar Documents

Publication Publication Date Title
GT200400242A (es) Uso extendido de combinacion que comprende estrogenos y progestina.
DK1259218T3 (da) Kosmetisk sammensætning til behandling af aldrende og/eller stresset hud
BR0107667A (pt) Composto de linezolida em forma de cristal que e farmaceuticamente útil como agente antibacteriano e método de preparação do mesmo
ES2162319T3 (es) Uso del agente quelante clioquinol para la fabricacion de una composicion farmaceutica para el tratamiento de la enfermedad de alzheimer.
BR0112054A (pt) Composição formadora de micelas, e métodos para a administração e a proteção de um agente terapêutico
DE60106954D1 (de) Resorcin-derivate
BR0115323A (pt) Uso de cci-779 como agente antineoplástico
BR0111358A (pt) Compostos de tioacetamida e seu uso
AR034900A1 (es) Uso de una cantidad eficaz de un inhibidor de pde4 y un agente anticolinergico, bien en forma combinada sola o por separado, composiciones farmaceuticas que los comprenden, metodo para prepararlas, y uso de una composicion que comprende una cantidad eficaz de un inhibidor de pde4, una cantidad efica
AR023806A1 (es) Uso de una mezcla de peptidos para la manufactura de un agente terapeutico para la profilaxis y/o el tratamiento del cancer, las composicionesfarmaceuticas y vacunas que contienen dicha mezcla y los procedimientos de preparacion de dichas composiciones y vacunas
BR0113751A (pt) Composições cosméticas e farmacêuticas e seus empregos
DE69921318D1 (de) Tensid für äusserlich anzuwendende hautpräparate und diese beinhaltende äusserlich anzuwendende hautpräparate
AR028959A1 (es) Uso de rapamicina para la manufactura de un medicamento para tratar enfermedades cardiovasculares
GT200000077A (es) Sal mutua de amlodipino y atorvastatina
CO5160321A1 (es) Novedosas composiciones de tipranavir y ritonavir
BR0014560B1 (pt) uso de uma composiÇço de tratamento de tecidos.
AR031761A1 (es) Kit de repinotano
CY1105317T1 (el) Χρηση υποκατεστημενων ενωσεων 6-διμεθυλαμινομεθυλο-1-φαινυλο-κυκλοεξανιου για τη θepαπεια της ακρατειας ουρων
CY1105142T1 (el) Χρηση υποκατεστημενων ενωσεων 6-διμεθυλαμινομεθυλο-1-φαινυλο-κυκλοεξανιου για τη θepαπεια της ακρατειας ουρων
ATE417608T1 (de) Arzneizusammensetzungen enthaltend modafinilverbindungen
ECSP034530A (es) Derivados de 6-metil-tramadol sustituido en o
UY26171A1 (es) Método y formulación farmacéutica para el tratamiento de la discinesia de aparición tardía
DK1220676T3 (da) Forebyggelse af colorektal cancer
ES2136954T3 (es) Utilizacion de al menos un agua termal de vichy como antagonista de sustancia p.
BR0115983A (pt) Uso de sarp-1 para o tratamento e/ou prevenção de escleroderma